Australia's most trusted
source of pharma news
Tuesday, 11 November 2025
Posted 10 November 2025 AM
Eli Lilly and Novo Nordisk have signed Most Favoured Nation (MFN) deals with the US, offering cut-price access to their weight-loss and other drugs in exchange for a three-year exemption from tariffs.
Pfizer, AstraZeneca and Merck have also struck MFN deals in recent months as Donald Trump has pushed to reduce drug prices for US citizens.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.